We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
-14.07%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.34B
AUM Growth
-$421M
(-15%)
Cap. Flow
+$11.7M
Cap. Flow
% of AUM
0.5%
Top 10 Holdings %
Top 10 Hldgs %
40.93%
Holding
221
New
9
Increased
52
Reduced
52
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$15.4M |
| 2 |
Medtronic
MDT
|
+$13.3M |
| 3 |
UnitedHealth
UNH
|
+$8.16M |
| 4 |
Intuitive Surgical
ISRG
|
+$7.42M |
| 5 |
Pfizer
PFE
|
+$7.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$17M |
| 2 |
AstraZeneca
AZN
|
+$11.3M |
| 3 |
Idexx Laboratories
IDXX
|
+$10.4M |
| 4 |
Viatris
VTRS
|
+$8.21M |
| 5 |
Omega Healthcare
OHI
|
+$6.92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.39% |
| 2 | Real Estate | 2.48% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
HCA Healthcare
HCA
$85.7B
| $9.25M | 0.4% |
74,335
| – | – |
|
52
Alnylam Pharmaceuticals
ALNY
$27.4B
| $9.2M | 0.39% |
126,176
| – | – |
|
|
LKFT
53
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
| $9.16M | 0.39% |
99,815
| – | – |
|
54
Sabra Healthcare REIT
SBRA
$5.38B
| $8.95M | 0.38% |
542,862
-181,744
| -25% | -$3.66M |
|
|
AMRN
55
Amarin Corp
AMRN
$298M
| $8.9M | 0.38% |
32,703
-4,999
| -13% | -$1.82M |
|
56
Edwards Lifesciences
EW
$50B
| $8.7M | 0.37% |
170,394
-59,694
| -26% | -$3.02M |
|
57
McKesson
MCK
$101B
| $8.7M | 0.37% |
78,720
-4,227
| -5% | -$527K |
|
|
FOLD
58
DELISTED
Amicus Therapeutics
FOLD
| $8.38M | 0.36% |
875,304
| – | – |
|
59
GSK
GSK
$104B
| $8.36M | 0.36% |
174,960
| – | – |
|
60
Cencora
COR
$60.7B
| $8.32M | 0.36% |
111,807
| – | – |
|
|
MDCO
61
DELISTED
Medicines Co
MDCO
| $8.21M | 0.35% |
428,992
+263,151
| +159% | +$6.12M |
|
62
Sanofi
SNY
$103B
| $7.81M | 0.33% |
179,900
| – | – |
|
|
LTC
63
LTC Properties
LTC
$2.06B
| $7.45M | 0.32% |
178,623
-31,050
| -15% | -$1.36M |
|
|
XLRN
64
DELISTED
Acceleron Pharma
XLRN
| $7.44M | 0.32% |
170,766
| – | – |
|
65
Smith & Nephew
SNN
$13.6B
| $6.93M | 0.3% |
185,478
| – | – |
|
|
DPLO
66
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $6.81M | 0.29% |
505,701
+66,700
| +15% | +$1.12M |
|
|
BPMC
67
DELISTED
Blueprint Medicines
BPMC
| $6.75M | 0.29% |
125,207
-20,794
| -14% | -$1.26M |
|
68
Exelixis
EXEL
$14.1B
| $6.68M | 0.29% |
339,435
-214,505
| -39% | -$3.82M |
|
69
ResMed
RMD
$30.3B
| $6.68M | 0.29% |
58,630
| – | – |
|
|
MPT
70
Medical Properties Trust
MPT
$2.81B
| $6.65M | 0.28% |
413,809
-63,600
| -13% | -$1.01M |
|
|
ESPR
71
DELISTED
Esperion Therapeutics
ESPR
| $6.54M | 0.28% |
142,289
-46,998
| -25% | -$2.26M |
|
|
PRAH
72
DELISTED
PRA Health Sciences, Inc.
PRAH
| $6.48M | 0.28% |
70,460
+38,000
| +117% | +$3.84M |
|
|
SHPG
73
DELISTED
Shire pic
SHPG
| $6.3M | 0.27% |
36,216
| – | – |
|
|
DOC
74
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $6.27M | 0.27% |
391,016
| – | – |
|
75
Align Technology
ALGN
$12.4B
| $6.25M | 0.27% |
29,860
+18,616
| +166% | +$4.7M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q4 2018 Portfolio in Review
As of Q4 2018, Tekla Capital Management held 221 positions worth $2.34B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Tekla Capital Management's Q4 2018 filing shows 9 new, 52 increased, 52 reduced and 18 closed positions. Its largest new stake was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M. The largest sale was Aetna Inc, an estimated $17M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate and Financials.
- Tekla Capital Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M.
- Tekla Capital Management added most to Bristol-Myers Squibb in Q4 2018, an estimated $15.4M increase.
- Tekla Capital Management's biggest Q4 2018 reduction was AstraZeneca, cutting an estimated $11.3M.
- Tekla Capital Management fully exited Aetna Inc in Q4 2018, selling an estimated $17M.
- Tekla Capital Management's ten largest holdings make up 41% of its $2.34B portfolio in Q4 2018.
- Tekla Capital Management opened 9 new positions and closed 18 in Q4 2018.
- Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.34B.
Based on Tekla Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.